Polarean Imaging PLC - London-based medical imaging technology developer - Announces that following statement on August 29, the reimbursement code for the Polarean Xenoview technology has been assigned to a new technology ambulatory payment classification code which corresponds to a payment range of between USD1,201 to USD1,300 as part of the 2023 medicare hospital outpatient prospective payment system final rule. Notes the codes enables healthcare providers a path to bill for "magnetic resonance imaging with inhaled hyperpolarised xenon-129 contrast agent, chest, including preparation and administration of agent."
Current stock price: 13.55 pence, down 3.2% in London on Tuesday
12-month change: down 76%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
polarean (POLX)